Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.

Expert opinion on drug safety（2023）

引用 0|浏览6

暂无评分

摘要

This study found potential new AEs signals and might provide important support for clinical monitoring and risk identification of upadacitinib.

查看译文

关键词

upadacitinib, pharmacovigilance, adverse events, post-marketing surveillance, FAERS, data mining

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要